HIỆU QUẢ VÀ TÍNH AN TOÀN CỦA PHÁC ĐỒ OXALIPLATIN KẾT HỢP TS-1 TRÊN BỆNH NHÂN UNG THƯ DẠ DÀY TÁI PHÁT, DI CĂN

Abstract

Objective: To evaluate the efficacy and safety of oxaliplatin plus TS-1 in the treatment of metastatic or recurrent gastric cancer at Institute of Oncology and Nuclear Medicine, Military Hospital 175. Subject and methods: A retrospective descriptive study of 62 patients diagnosed of metastatic or recurrent gastric cancer from 1/2019 to 6/2024 at Institute of Oncology and Nuclear Medicine, Military Hospital 175. Result: The overall response rate was 43.6% with 8.1% complete response, clinical benefit rate was 74.2%. One-organ metastases and treated with surgical resection of the gastric cancer were good predictors of ORR. Common hematological toxicities were anemia 71.0% and thrombocytopenia 45.1%, grade 1 – 2 toxicities were common, grade 3 – 4 toxicities were low. Common non-hematological toxicities were peripheral neuropathy 71.0% and increased AST and/ or ALT 62.9%, mostly grade 1 – 2 toxicities and being well controlled. Conclusion: Regimen of oxaliplatin plus TS-1 in metastatic or recurrent gastric cancer is effective and safe.